Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s share price was up 1.6% on Monday . The company traded as high as $23.66 and last traded at $23.57. Approximately 243,417 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 368,726 shares. The stock had previously closed at $23.19.
Chugai Pharmaceutical Stock Performance
The stock has a market cap of $77.57 billion, a P/E ratio of 29.10 and a beta of 0.66. The firm's 50 day moving average is $25.35 and its 200 day moving average is $24.44.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. The firm had revenue of $1.89 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. As a group, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.
Chugai Pharmaceutical Company Profile
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
